What is the equity of Oragenics this year?
Oragenics has equity of 3.17 M USD this year.
Oragenics Equity 2024
Oragenics Equity
3.17 M USD
Ticker
OGEN
ISIN
US6840233026
WKN
A2JBK2
In 2024, Oragenics's equity was 3.17 M USD, a -75.65% increase from the 13.01 M USD equity in the previous year.
Oragenics Aktienanalyse
What does Oragenics do?
Oragenics Inc is a biopharmaceutical company that focuses on the development of innovative technologies and products for the prevention and treatment of oral and systemic infectious diseases. The company was founded in 1996 as a private company and has since had an impressive track record in the development of diagnostic tools and therapeutics for various diseases in different fields. The company's business model is based on the identification and development of therapeutics that leverage innovative technologies such as bacterial toxins and probiotics. Their products aim to address both the causes of disease formation and the symptoms, contributing to improved patient well-being. Oragenics maintains partnerships and collaborations with other companies and research institutions to enhance its research and development efforts. The company is divided into multiple divisions, including the development of probiotic bacterial groups with specific immunotherapeutic functions, the development of biopharmaceutical products for the treatment of infectious diseases, and the development of diagnostics and screening tools for identifying oral infections. Oragenics has developed a range of products and technologies that can contribute to the improvement of oral and overall health, including a Streptococcus mutans detection system for dentists to identify and combat bacteria in the patient's mouth. One notable product is the TerraCoV2 COVID-19 vaccine, developed in collaboration with the National University of Singapore. Overall, Oragenics Inc has a remarkable track record in the development of innovative technologies and products, emphasizing product quality, rational manufacturing, and a wide range of medical devices. The company works closely with partners and collaborators to intensify its research and development efforts and provide innovative solutions and products. Oragenics ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Oragenics's Equity
Oragenics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Oragenics's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Oragenics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Oragenics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Oragenics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Oragenics stock
What was the equity of Oragenics compared to the previous year?
The equity of Oragenics has increased/decreased by -75.65% decreased compared to the previous year.
What impact does a high equity have on investors of Oragenics?
A high equity is advantageous for investors of Oragenics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Oragenics?
A low equity can be a risk for investors of Oragenics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Oragenics affect the company?
An increase in equity of Oragenics can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Oragenics affect the company?
A reduction in equity of Oragenics can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Oragenics?
Some factors that can affect the equity of Oragenics include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Oragenics so important for investors?
The equity of Oragenics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Oragenics take to change the equity?
To change equity, Oragenics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Oragenics pay?
Over the past 12 months, Oragenics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oragenics is expected to pay a dividend of 0 USD.
What is the dividend yield of Oragenics?
The current dividend yield of Oragenics is .
When does Oragenics pay dividends?
Oragenics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Oragenics?
Oragenics paid dividends every year for the past 0 years.
What is the dividend of Oragenics?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Oragenics located?
Oragenics is assigned to the 'Health' sector.
Wann musste ich die Aktien von Oragenics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Oragenics from 12/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/20/2024.
When did Oragenics pay the last dividend?
The last dividend was paid out on 12/20/2024.
What was the dividend of Oragenics in the year 2023?
In the year 2023, Oragenics distributed 0 USD as dividends.
In which currency does Oragenics pay out the dividend?
The dividends of Oragenics are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Oragenics
Our stock analysis for Oragenics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oragenics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
